ApolloMed 2022 revenue $1.14B (+48% YoY), net income $49M, adj. EBITDA $140M

Astrana Health, Inc.

2022-FY EPS reported $1.08 revenue$1,144,163,000

Total revenue $1.14B for 2022, up 48% from $773.9M in 2021.
Net income attributable to ApolloMed $49.0M; diluted EPS $1.08.
Adjusted EBITDA $140.0M, up 5% from $133.5M; margin 12.2%.
Cash and equivalents $288.0M at Dec 31, 2022.
Conference call scheduled Feb 24, 2023 at 8:30 a.m. ET.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Astrana Health, Inc. reported the quarter and year ended December 31, 2022 results: revenue $1.14 billion, net income $49.0 million, EPS $1.08.

Period: the quarter and year ended December 31, 2022
Revenue: $1.14 billion
Net income: $49.0 million
EPS: $1.08
Result: reported results

Exact text from the filing

• Total revenue of $1.14 billion, an increase of 48% from $773.9 million for the prior year • Net income attributable to ApolloMed of $49.0 million • Earnings per share — diluted (“EPS — diluted”) of $1.08

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Astrana Health, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-004894

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.